⌕
Cara Therapeutics · TVRD · Nasdaq
Tenet 47 · Mixed
Compare
$0.95−9.03%At closeTenet 47 · Mixed
$0.95−0.09 (−9.03%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD

Cara Therapeutics (TVRD) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● GlobeNewsWireNov 19, 2026 · 08:00 ET
Tvardi Therapeutics Advances Next-Generation Oral STAT3 Inhibitor TTI-109 Toward IND in Inflammatory Bowel Disease Following FDA Pre-IND Feedback

HOUSTON, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapi…

● GlobeNewsWireNov 13, 2026 · 07:00 ET
Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update

HOUSTON, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therap…

● GlobeNewsWireOct 14, 2026 · 08:00 ET
Tvardi Therapeutics to Participate in Chardan's 10th Annual Healthcare Conference

HOUSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapi…

● Defense WorldOct 1, 2026 · 06:15 ET
Head-To-Head Survey: Tvardi Therapeutics (NASDAQ:TVRD) versus Phibro Animal Health (NASDAQ:PAHC)

Tvardi Therapeutics (NASDAQ: TVRD - Get Free Report) and Phibro Animal Health (NASDAQ: PAHC - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies …

● GlobeNewsWireSep 24, 2026 · 08:00 ET
New Preclinical Data Further Support Potential for Tvardi's STAT3 Inhibitors in Ulcerative Colitis (UC)

In a preclinical chronic colitis model, Tvardi's oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and modulated STAT3-driven…

● GlobeNewsWireAug 26, 2026 · 08:00 ET
Tvardi Therapeutics to Participate in Upcoming Investor Events

HOUSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STA…

No recent releases where the company itself is speaking.

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

ANT13−7.0%
AAPL8+0.3%
FOX6−2.9%
META6−2.2%

Article counts from the last market-wide feed page, across every symbol we track and not just TVRD · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.